Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction

European Heart Journal

Volumn 27, Issue 10, 2006, Pages 1153-1158

  Gislason, Gunnar H ^a,b   Rasmussen, Jeppe N ^b   Abildstrøm, Steen Z ^b,c   Gadsbøll, Niels ^d   Buch, Pernille ^a,b   Friberg, Jens ^a   Rasmussen, Søren ^b   Køber, Lars ^e   Stender, Steen ^c   Madsen, Mette ^b   Torp Pedersen, Christian ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

ACE inhibitors; Acute myocardial infarction; Beta blockers; Compliance; Pharmacological treatment; Statins

Indexed keywords

ANTIDIABETIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOOP DIURETIC AGENT; METOPROLOL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; STATINE DERIVATIVE; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; DOSE RESPONSE; FEMALE; GENDER; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DENMARK; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 33646750506     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi705     Document Type: Article

References (24)

1. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-1582.
2. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
3. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-130.
4. Gislason G, Abildstrom S, Rasmussen J, Rasmussen S, Buch P, Gustafsson I, Friberg J, Gadsbøll N, Køber L, Stender S, Madsen M, Torp-Pedersen C. Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002. Scand Cardiovasc J 2005;39:42-49.
5. Rasmussen J, Gislason G, Abildstrom S, Rasmussen S, Gustafsson I, Buch P, Friberg J, Køber L, Torp-Pedersen C, Madsen M, Stender S. Statin use after acute myocardial infarction: a Danish nationwide study. Br J Clin Pharmacol 2005;60:150-158.
6. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, Steg PG. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73-81.
7. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003;145:438-444.
8. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467.
9. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-261.
10. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002;53:375-378.
11. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Platt R. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
12. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-1462.
13. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461.
14. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003;92:1106-1108.
15. Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 2004;47:11-33.
16. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
17. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-828.
18. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
19. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
23. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:89-103.
24. Abildstrom SZ, Rasmussen S, Madsen M. Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 2005;26:990-995.